The cost of proband and trio exome and genome analysis in rare disease: A micro-costing study

Dylan A. Mordaunt, Francisco Santos Gonzalez, Sebastian Lunke, Stefanie Eggers, Simon Sadedin, Belinda Chong, Kim Dalziel, Zornitza Stark, Ilias Goranitis

Research output: Contribution to journalArticlepeer-review

9 Downloads (Pure)

Abstract

Purpose: Rare disease genomic testing is a complex process involving various resources. Accurate resource estimation is required for informed prioritization and reimbursement decisions. This study aims to analyze the costs and cost drivers of clinical genomic testing. 

Methods: Based on genomic sequencing workflows we microcosted limited virtual panel analysis on exome sequencing backbone, proband and trio exome, and genome testing for proband and trio analysis in 2023 Australian Dollars ($). Deterministic and probabilistic sensitivity analyses were undertaken. 

Results: Panel testing costs AUD $2373 ($733-$6166), and exome sequencing costs $2823 ($802-$7206) and $5670 ($2006-$11,539) for proband and trio analysis, respectively. Genome sequencing costs $4840 ($2153-$9890) and $11,589 ($5842-$16,562) for proband and trio analysis. The most expensive cost component of genomic testing was sequencing (36.9%-69.4% of total cost), with labor accounting for 27.1%-63.2% of total cost. 

Conclusion: We provide a comprehensive analysis of rare disease genomic testing costs, for a range of clinical testing types and contexts. This information will accurately inform economic evaluations of rare disease genomic testing and decision making on policy settings that assist with implementation, such as genomic testing reimbursement.

Original languageEnglish
Article number101058
Number of pages8
JournalGENETICS IN MEDICINE
Volume26
Issue number4
Early online date30 Dec 2023
DOIs
Publication statusPublished - Apr 2024
Externally publishedYes

Keywords

  • Genomics
  • Health care Financing
  • Health Policy
  • Microcosting
  • Rare Disease

Fingerprint

Dive into the research topics of 'The cost of proband and trio exome and genome analysis in rare disease: A micro-costing study'. Together they form a unique fingerprint.

Cite this